GridAI Technologies Corp.
GRDXNasdaq
$3.82
↑ +0.3%Jul 17 close · end-of-day
Price
1Y↑ +182.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$17.0M
Enterprise Value
$16.6M
P/E
—
P/S
—
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
—
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
—
ROIC
-33.6%
Debt / Equity
—
Net Cash
$385,542.00
Return 1Y
+169.1%
Company profile
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.
- CEO
- James E. Sapirstein
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 9
- Headquarters
- Florida
- Website
- www.enterothera.com
Management & directors
- Sawyer Jason DavidChief Executive Officer
- Skowron AnnaInterim CFO
Roles derived from SEC Form 4 filings.
Earnings
GRDX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$38,208.00—
Diluted EPS-$0.82↓ -2.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $36,251.00 |
| Gross profit | — | — | — | — | — | -$657,432.00 |
| Operating income | -$26.4M | -$59.1M | -$12.7M | -$15.8M | -$15.6M | -$7.1M |
| Net income | -$32.7M | -$58.5M | -$14.6M | -$15.8M | -$18.1M | -$6.4M |
| Diluted EPS | -$14.68 | -$1,988.53 | -$416.94 | -$47.88 | -$15.99 | -$4.16 |
| Operating cash flow | -$11.2M | -$32.3M | -$22.3M | -$12.4M | -$9.2M | -$5.7M |
| Free cash flow | -$11.2M | -$32.4M | — | — | — | — |
| Gross margin | — | — | — | — | — | -1813.6% |
| Operating margin | — | — | — | — | — | -19540.0% |
| Net margin | — | — | — | — | — | -17634.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $38,208.00 |
| Gross profit | — | — | — | — | — | — | — | -$613,740.00 |
| Operating income | -$3.4M | -$1.9M | -$1.2M | -$821,386.00 | -$638,864.00 | -$934,787.00 | -$4.7M | -$3.6M |
| Net income | -$8.8M | -$2.6M | -$12.2M | -$1.3M | -$998,271.00 | -$1.2M | -$3.0M | — |
| Diluted EPS | -$3.86 | -$1.76 | -$10.75 | -$0.84 | -$0.21 | -$0.75 | -$2.36 | -$0.82 |
| Operating cash flow | -$3.5M | -$1.8M | -$171,518.00 | -$818,635.00 | -$54,878.00 | -$855,688.00 | -$4.0M | -$1.8M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | -1606.3% |
| Operating margin | — | — | — | — | — | — | — | -9460.1% |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Dec 5, 2025
Nov 19, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Sawyer Jason David· Chief Executive Officer | Award | 250,000 | $0.00 | $0.00 | filing |
| 2026-03-31 | Sawyer Jason David· Chief Executive Officer | Award | 250,000 | $0.00 | $0.00 | filing |
| 2026-01-01 | Syage Jack | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-01-01 | BORKOWSKI EDWARD | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-01-01 | Uppal Manpreet | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-01-01 | Pursglove Geordan Garrett | Award | 40,000 | $0.00 | $0.00 | filing |
| 2025-12-22 | Sawyer Jason David· Chief Executive Officer | Award | 40,000 | $0.00 | $0.00 | filing |
| 2025-12-22 | Skowron Anna· Interim CFO | Award | 65,000 | $0.00 | $0.00 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.